DAFNA Capital Management »

Fulcrum Therapeutics shares owned by DAFNA Capital Management

Quarter-by-quarter ownership of Fulcrum Therapeutics (FULC) shares owned by DAFNA Capital Management from 13F filings

Historical chart of DAFNA Capital Management investment in Fulcrum Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Fulcrum Therapeutics held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Fulcrum Therapeutics by DAFNA Capital Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $1.6M 205k 7.67

More positions owned by DAFNA Capital Management

Revolution Medicines (RVMD)
Spdr S&p Biotech Etf Etf (XBI)
Stereotaxis Com New (STXS)
Day One Biopharmaceuticals I (DAWN)
AtriCure (ATRC)
Ideaya Biosciences (IDYA)
Xenon Pharmaceuticals (XENE)
Cytokinetics Com New (CYTK)
Compass Pathways Sponsored Ads (CMPS)
Nektar Therapeutics Com New (NKTR)
Ishares Nasdaq Biotech Indx Etf (IBB)
Arcus Biosciences Incorporated (RCUS)
Neurocrine Biosciences (NBIX)
Larimar Therapeutics (LRMR)
Bicara Therapeutics (BCAX)

View all positions for DAFNA Capital Management

Top funds holding Fulcrum Therapeutics

Suvretta Capital Management
RA Capital Management
BlackRock
TCG Crossover Management
Vanguard Group
Braidwell
Nantahala Capital Management
Vanguard Capital Management
Standard Life Aberdeen
Balyasny Asset Management
Point72 Asset Management
Siren
First Turn Management
Jones Hill Capital
Adage Capital Partners GP

View all funds holding Fulcrum Therapeutics